Navigation Links
Metabolex Initiates Phase 2 Trial of Arhalofenate
Date:5/19/2011

HAYWARD, Calif., May 19, 2011 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today that it has initiated a Phase 2 clinical trial of arhalofenate (MBX-102), its product candidate for the management of hyperuricemia in patients with gout.

This randomized, double-blind, placebo-controlled study will evaluate the safety and urate-lowering activity of 400 and 600 mg of arhalofenate in 60 patients with hyperuricemia and a diagnosis of gout. The primary endpoint of the study is the percent reduction in serum uric acid levels from baseline following four weeks of treatment. As part of its broader Phase 2 program, Metabolex will also be initiating a combination study with allopurinol in patients refractory to allopurinol and a combination study with febuxostat (Uloric®, Takeda Pharmaceutical Company Limited; Adenuric®, Ipsen and Menarini).

Arhalofenate is a novel, orally administered, small molecule uricosuric agent that was previously under development by Metabolex for Type 2 diabetes. Arhalofenate has completed eight Phase 1 and four Phase 2 studies which demonstrate that it has excellent safety and tolerability in more than 550 patients for up to six months of treatment. During this development program, it was observed that once daily dosing with arhalofenate not only lowers glucose and triglycerides, but also results in robust, dose-dependent reductions in serum uric acid through its uricosuric activity. The uric acid reductions were fully retained in patients with mild-to-moderate renal insufficiency. Thus, arhalofenate is a potential best-in-class uricosuric agent that not only corrects the hyperuricemia associated with gout, but also addresses other aspects of metabolic syndrome seen in patients with gout.

"We are excited about initiating our gout trials. Our Phase 2 program is designed to show that a
'/>"/>

SOURCE Metabolex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Metabolex Announces Election of Kurt von Emster to Board of Directors
2. Metabolex Announces Positive Results From Phase 1a Clinical Trial of MBX-2982
3. Two Metabolex Projects Recognized in Windhovers Top 10 Lists for Partnering Opportunities
4. Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline
5. TissueGene Initiates Patient Enrollment for a Phase II Study of TG-C for Osteoarthritis of the Knee
6. Proteon Therapeutics Initiates Patient Enrollment in Phase 2 Clinical Study of PRT-201 in Hemodialysis Patients
7. S*BIO Initiates Phase 2 Clinical Trial of its Novel JAK2 Inhibitor SB1518 in North America for Advanced Lymphoid Malignancies
8. Stephens Initiates Coverage on Vermillion
9. Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
10. American Regent Initiates Voluntary Nationwide Recall of Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL, 1 mL Single Dose Vials; 5 mL and 30 mL Multiple Dose Vials
11. CalciMedica Initiates Phase I Clinical Trial of First CRAC Channel Inhibitor (CCI) for Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Two champions of ... their sponsorship of an annual competition for middle and ... access to, innovative STEM study. The competition presents students ... Tests of Engineering Aptitude, Mathematics, and Sciences is ...
(Date:1/15/2014)... 2014 AudioNotch is the internet's leading ... the treatment of tinnitus. Patients listen to sound therapy ... a period of weeks to months, their tinnitus volume decreases. ... forms: Notched Music and Notched White Noise. Now, AudioNotch is ...
(Date:1/14/2014)...  3D Communications, a leading provider of strategic communications services to corporations ... in the United States and ... , JD, is returning to the firm,s Washington, D.C. ... after more than two years of service as Associate Commissioner for ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, today ... In this role, Michelle will work with current and potential ... development of iLab products. Her main goal will be to ... scientific community by offering the most advanced, user-friendly, and high-impact ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Former FDA Associate Commissioner Returns To 3D Communications 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... faculty members will explore energy from the ocean, manufacturing ... to prestigious Faculty Early Career Development (CAREER) Awards from ... million over five years, went to assistant professors Yannis ... and Wheeler Ruml of the computer science department. ...
... Calif., Feb. 21, 2012  Life Technologies Corporation (NASDAQ: ... Barclays Capital Global Healthcare Conference on Wednesday, March 14 ... Vice President and Chief Financial Officer, will present on ... presentation, which will be available for three weeks following ...
... leaders from the medical community in Europe and the U.S. ... liver disease and sepsis, and in cardiac surgery, during ... "Albumin in Clinical Fluid Management ." (Logo: ... a frank and provocative exchange about the uses and effectiveness ...
Cached Biology Technology:NSF CAREER grants support ocean energy, microforming, computer planning 2Life Technologies to Present at Barclays Capital Global Healthcare Conference 2Medical Experts Who Participated in CSL Behring's Key Issues Dialogue Prefer Albumin for Fluid Management 2Medical Experts Who Participated in CSL Behring's Key Issues Dialogue Prefer Albumin for Fluid Management 3
(Date:4/18/2014)... X-ray crystallography and nuclear magnetic resonance imaging (NMR) to ... but such efforts have long been hampered by the ... molecule and often in ordered and crystalized form to ... peer into the structure of most molecules. , Harvard ... thing of the past. , A team of ...
(Date:4/18/2014)... Asteroid and comet impacts can cause widespread ecological havoc, ... global scales. But new research from Brown University shows ... life at the time of an impact. , A ... found fragments of leaves and preserved organic compounds lodged ... Argentina. The material could provide a snapshot of environmental ...
(Date:4/17/2014)... for chili peppers. Information about archaeological remains of ancient ... the appearance of words for chili peppers in ancient ... and highlight the value of multi-proxy data analysis. Their ... nine papers presented in a special feature issue of ... on plant and animal domestication edited by Dolores ...
Breaking Biology News(10 mins):MRI, on a molecular scale 2MRI, on a molecular scale 3Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3Chickens to chili peppers 2Chickens to chili peppers 3
... team of researchers at the University of Pittsburgh has ... HIV, that could be potential treatments for drug-resistant bacterial ... agents are quite small, making them inexpensive and easy ... 2013 issue of the journal Antimicrobial Agents and ...
... A new variety of canary seeds bred specifically for human ... for people with celiac disease (CD), scientists have confirmed in ... Food Chemistry . Joyce Irene Boye and colleagues ... United States alone have CD. They develop gastrointestinal and other ...
... Agency (EMA) approved the modified adeno-associated virus AAV-LPL S447X ... in the Western world. uniQure, a Dutch biotech company, ... rare inherited metabolic disease called lipoprotein lipase deficiency (LPLD) ... million people. The disease causes severe, life-threatening inflammations of ...
Cached Biology News:HIV-derived antibacterial shows promise against drug-resistant bacteria 2No danger of cancer through gene therapy virus 2
Human endothelial progenitor cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Yeast tRNA 50 l...
Human monocyte-derived dendritic cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
...
Biology Products: